The Future of Hiv Care - Long Term Remission and Eliminating Co-Morbidities

Methaneseleninic acid, a circadian-modulating agent, reactivates latent HIV-1 infection without cellular activation or proliferation

J Stern, RA Shepherd, Y Kim, C Tumpach, KE Amos, OH Lloyd Williams, S Varshney, HAD King, A Rhodes, SR Lewin, M Roche

2026-03-01

Human immunodeficiency virus (HIV)-1 transcriptional activity is under circadian control in virally suppressed people with HIV (PW..

The effect of combining HIV latency reversal with inhibition of phosphoinositide-3 kinases or B-cell lymphoma-2 on the HIV reservoir

Y Kim, JL Anderson, C Tumpach, A Solomon, J Ong, K Tanaka, JM Zerbato, T Tan, CE Teh, DHD Gray, P Arandjelovic, J McMahon, N Meager, D Price, M Pellegrini, M Roche, SR Lewin

2026-01-01

The persistence of latently infected CD4 + T-cells in people with HIV (PWH) on suppressive antiretroviral therapy (ART) is the maj..

Limitations and use of the Morpheus-V5 dual reporter virus in assessing interventions that target HIV latency

K Tanaka, Y Kim, J Ong, C Tumpach, A Rhodes, HA King, AC Hearps, M Roche, SR Lewin

2025-12-01

HIV can persist indefinitely in latently infected CD4 + T-cells as an integrated provirus with limited or no viral transcription a..

The impact of acute stress on the HIV reservoir: a prospective interventional trial

J Stern, M Roche, R Shepherd, W Hartogensis, P Moran, L Cockerham, N Saraya, A Rhodes, PU Cameron, JJ Chang, N Kumar, WB Mendes, SG Deeks, FM Hecht, SR Lewin

2025-12-01

The persistence of latently infected CD4⁺T cells is the major barrier to cure of people with HIV (PWH) on antiretrovira..

CRISPR/Cas9 for achieving postintervention HIV control

MA Moso, M Roche, PM Cevaal, SR Lewin

2025-09-01

Purpose of reviewRecent advances in gene therapy have led to the first clinically approved CRISPR/Cas9 therapy for β-thalassaemia ..

Efficient mRNA delivery to resting T cells to reverse HIV latency

PM Cevaal, S Kan, BM Fisher, MA Moso, A Tan, H Liu, A Ali, K Tanaka, RA Shepherd, Y Kim, J Ong, DL Furtado, M Holz, DFJ Purcell, JML Casan, T Payne, W Zhao, M Fareh, JH McMahon, SG Deeks

2025-05-29

A major hurdle to curing HIV is the persistence of integrated proviruses in resting CD4+ T cells that remain in a transcriptionall..

HIV and the gut: implications for HIV persistence, immune dysfunction and cure strategies

JSY Lau, SR Lewin, S Telwatte

2025-01-01

The intestinal immune compartment plays a central role in HIV pathogenesis, serving as an early site for viral replication and a s..

HIV Tat as a latency reversing agent: turning the tables on viral persistence

BM Fisher, PM Cevaal, M Roche, SR Lewin

2025-01-01

The ‘shock and kill’ approach to an HIV cure involves the use of latency reversing agents (LRAs) to reactivate latent HIV, with th..

Circulating capsid-antibody-complexes (CACs) drive intrahepatic complement deposition and inform subclinical liver inflammation in chronic hepatitis B

Y Tang, M Xu, C Wang, M Wu, L Hu, J Li, W Lu, Y Zheng, M Zhang, X Jiang, C Zhu, J Audsley, P Tangkijvanich, A Avihingsanon, S Song, S Liu, SR Lewin, J George, M Douglas, Y Ling

2024-11-01

Chronic infection with Hepatitis B Virus (HBV) often results in a dysfunctional virus-specific T cell response hampering viral cle..

Impact of a TLR9 agonist and broadly neutralizing antibodies on HIV-1 persistence: the randomized phase 2a TITAN trial

JD Gunst, JF Højen, MH Pahus, M Rosás-Umbert, B Stiksrud, JH McMahon, PW Denton, H Nielsen, IS Johansen, T Benfield, S Leth, J Gerstoft, L Østergaard, MH Schleimann, R Olesen, H Støvring, L Vibholm, N Weis, AM Dyrhol-Riise, KBH Pedersen

2023-10-01

Inducing antiretroviral therapy (ART)-free virological control is a critical step toward a human immunodeficiency virus type 1 (HI..

Adaptation of the intact proviral DNA assay to a nanowell-based digital PCR platform

C Tumpach, CR Cochrane, Y Kim, J Ong, A Rhodes, TA Angelovich, MJ Churchill, SR Lewin, S Telwatte, M Roche

2023-06-01

Quantification of intact proviruses is a critical measurement in HIV cure studies both in vitro and in vivo. The widely adopted ‘i..

HIV DNA persists in hepatocytes in people with HIV-hepatitis B co-infection on antiretroviral therapy

JM Zerbato, A Avihingsanon, KP Singh, W Zhao, C Deleage, E Rosen, ML Cottrell, A Rhodes, A Dantanarayana, C Tumpach, S Tennakoon, M Crane, DJ Price, S Braat, H Mason, M Roche, ADM Kashuba, PA Revill, J Audsley, SR Lewin

2023-01-01

Background: HIV can infect multiple cells in the liver including hepatocytes, Kupffer cells and infiltrating T cells, but whether ..

Soluble immune checkpoints as correlates for HIV persistence and T cell function in people with HIV on antiretroviral therapy

CY Chiu, MD Schou, JH McMahon, SG Deeks, R Fromentin, N Chomont, MN Wykes, TA Rasmussen, SR Lewin

2023-01-01

Introduction: In people with HIV (PWH) both off and on antiretroviral therapy (ART), the expression of immune checkpoint (IC) prot..

Antiretroviral Initiation at ≥800 CD4 Cells/mm3Associated with Lower Human Immunodeficiency Virus Reservoir Size

TA Rasmussen, SK Ahuja, L Kuwanda, MJ Vjecha, F Hudson, L Lal, A Rhodes, J Chang, S Palmer, P Auberson-Munderi, H Mugerwa, R Wood, S Badal-Faesen, S Pillay, R Mngqibisa, A Larosa, J Hildago, K Petoumenos, C Chiu, J Lutaakome

2022-11-15

Background: Identifying factors that determine the frequency of latently infected CD4+T cells on antiretroviral therapy (ART) may ..

Balancing Statistical Power and Risk in HIV Cure Clinical Trial Design

JSY Lau, D Cromer, M Pinkevych, SR Lewin, TA Rasmussen, JH McMahon, MP Davenport

2022-07-15

Background. Analytical treatment interruptions (ATI) are pauses of antiretroviral therapy (ART) in the context of human immunodefi..

Cell-Associated Human Immunodeficiency Virus (HIV) Ribonucleic Acid Has a Circadian Cycle in Males With HIV on Antiretroviral Therapy

J Stern, A Solomon, A Dantanarayana, R Pascoe, A Reynaldi, MP Davenport, J Milush, SG Deeks, W Hartogensis, FM Hecht, L Cockerham, M Roche, SR Lewin

2022-05-15

Background: Circadian transcription factors that regulate cell-autonomous circadian clocks can also increase human immunodeficienc..

Immune checkpoint blockade in HIV

C Gubser, C Chiu, SR Lewin, TA Rasmussen

2022-02-01

Antiretroviral therapy (ART) has dramatically improved life expectancy for people with HIV (PWH) and helps to restore immune funct..

Combination Immune Checkpoint Blockade Enhances IL-2 and CD107a Production from HIV-Specific T Cells Ex Vivo in People Living with HIV on Antiretroviral Therapy

CY Chiu, JJ Chang, AI Dantanarayana, A Solomon, VA Evans, R Pascoe, C Gubser, L Trautman, R Fromentin, N Chomont, JH McMahon, PU Cameron, TA Rasmussen, SR Lewin

2022-01-01

In people with HIV (PWH) on antiretroviral therapy (ART), immune dysfunction persists, including elevated expression of immune che..

Integrated immune dynamics define correlates of COVID-19 severity and antibody responses

M Koutsakos, LC Rowntree, L Hensen, BY Chua, CE van de Sandt, JR Habel, W Zhang, X Jia, L Kedzierski, TM Ashhurst, GH Putri, F Marsh-Wakefield, MN Read, DN Edwards, EB Clemens, CY Wong, FL Mordant, JA Juno, F Amanat, J Audsley

2021-03-16

SARS-CoV-2 causes a spectrum of COVID-19 disease, the immunological basis of which remains ill defined. We analyzed 85 SARS-CoV-2-..

Multiply spliced HIV RNA is a predictive measure of virus production ex vivo and in vivo following reversal of HIV latency

JM Zerbato, G Khoury, W Zhao, MJ Gartner, RD Pascoe, A Rhodes, A Dantanarayana, M Gooey, J Anderson, P Bacchetti, SG Deeks, J McMahon, M Roche, TA Rasmussen, DF Purcell, SR Lewin

2021-03-01

Background: One strategy being pursued to clear latently infected cells that persist in people living with HIV (PLWH) on antiretro..

Intrahepatic CXCL10 is strongly associated with liver fibrosis in HIV-Hepatitis B coinfection

KP Singh, JM Zerbato, W Zhao, S Braat, C Deleage, G Surekha Tennakoon, H Mason, A Dantanarayana, A Rhodes, JW Rhodes, J Torresi, AN Harman, PA Revill, M Crane, JD Estes, A Avihingsanon, SR Lewin, J Audsley

2020-09-08

In HIV-hepatitis B virus (HBV) co-infection, adverse liver outcomes including liver fibrosis occur at higher frequency than in HBV..

Longitudinal analysis of subtype C envelope tropism for memory CD4 T cell subsets over the first 3 years of untreated HIV-1 infection

MJ Gartner, PR Gorry, C Tumpach, J Zhou, A Dantanarayana, JJ Chang, TA Angelovich, P Ellenberg, AE Laumaea, M Nonyane, PL Moore, SR Lewin, MJ Churchill, JK Flynn, M Roche

2020-08-06

Background: HIV-1 infects a wide range of CD4+ T cells with different phenotypic properties and differing expression levels of ent..

A gathering storm: HIV infection and nonalcoholic fatty liver disease in low and middle-income countries

N Kapoor, J Audsley, P Rupali, J Sasadeusz, TV Paul, N Thomas, SR Lewin

2019-06-01

Despite the decreasing total incidence of liver-related deaths, liver disease remains one of the major non-AIDS causes of morbidit..

HIV latency reversing agents act through Tat post translational modifications

G Khoury, TM Mota, S Li, C Tumpach, MY Lee, J Jacobson, L Harty, JL Anderson, SR Lewin, DFJ Purcell

2018-05-11

Background: Different classes of latency reversing agents (LRAs) are being evaluated to measure their effects in reactivating HIV ..

HIV cure research: print and online media reporting in Australia

Jennifer Power, Bianca Fileborn, Gary W Dowsett, Jayne Lucke, Graham Brown, Jeanne Ellard, Sharon R Lewin, Joseph D Tucker, Sean Slavin, Jeremy Sugarman, Sophie Hill

2017-10-01

OBJECTIVES: While still in its early stages, recent scientific research towards a cure for HIV has generated widespread media inte..